RA Capital Management formed a new blank-check entity, “Research Alliance III,” targeting a merger or acquisition with a biotechnology or healthcare company in China. The venture firm plans to sell 5 million shares in the SPAC at $10 apiece to fund searches and capital deployment. In its filing, RA Capital cited the “current state” of the biotechnology IPO market as a reason it expects improved ability to locate an attractive target. The SPAC is designed to capitalize on investor demand for drug company IPOs even as public market conditions have tightened. The structure also signals how investors view China as an asset pool for late-stage and development-stage programs, with RA Capital pointing to the ecosystem that has produced a large inventory of drug licensing deals. This aligns with the firm’s past SPAC activity, including a merger with Point Biopharma and other prior deals. For biotech, the announcement is a potential accelerant for clinical-stage China-linked assets to reach public markets through alternative pathways, particularly if the IPO window stays constrained.